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Primary (AL type) amyloidosis is the most common form of systemic amyloidosis. The morbidity arises
from extracellular deposition of immunoglobulin light chain (LC) ﬁbrils in some organs such as the
kidneys, heart and bowel. Primary amyloidosis and multiple myeloma both involve clonal plasma cell
proliferation. Distinctive haematological and biochemical laboratory ﬁndings may help in early diagnosis.
Here we present a 60-year-old man with an exceptional clinical course of an Ig A type multiple myeloma
with generalized amyloidosis, causing nephrotic syndrome, complete intestinal colitis and mal-
absorbtion. Our comprehensive overview of this rare and often fatal disease aims to increase the
awareness of AL type amyloidosis. This may facilitate earlier diagnosis and thus allow initiation of
prompt and speciﬁc therapies, which are indispensable in order to improve disease prognosis.
 2010 Elsevier Ltd. All rights reserved.1. Case report
A 60-year-old male patient applied to internal medicine outpa-
tient clinics for chronic diarrhea and fatigue. His diarrhea had been
persisting for ten days, the passage of 5e6 times a day with large
volumes, accompanying nausea, vomiting but without blood or
abdominal pain. He had a cachectic face and bilateral pretibial þ/þ
edema. Other physical examination ﬁndings were normal. Labora-
tory examination was as follows: white blood cell: 7700/mm3, red
blood cell: 3,920,000/mm3, hemoglobin: 9.5 g/dL, platelet:
630,000/mm3, erithrocyte sedimentation rate: 100 mm/h, CRP:
168 ng/l, albumin: 2.44 g/dL, INR: 1.16, urinary protein: þþ. There
were no fecal leukocytes in the stool and the stool bacterial culture
was negative. The ovum and parasite evaluation in the stool was
negative. Abdominal ultrasonography showed hepatomegaly and
heterogenity of liver parenchyma. Eosophagoduodenoscopy
showed pangastritis and duodenitis. The endoscopic biopsy
revealed gluten enteropathy. His anti-endomissium antibody IgA
and Ig Gwere negative, anti-gliadin IgA antibodywas 6 IU/mL, anti-
gliadin Ig G antibody was <2 IU/mL. There were multiple polipoid
lesions on colonoscopy and the biopsy was tubular adenoma.
Computed tomography (CT) scan revealed multiple mediastinal
lymphadenopathies and the biggest onewas 65 mm. Bronchoscopic
biopsywas performed and nontuberculousmycobacteria growed inx: þ90 312 3044000.
aradurmus).
rved.the culture. But there was no sign of granulamatous lesion histo-
pathologically. No clinical ﬁnding resembling tuberculosis infection
was existing. He was diagnosed as gluten entheropathy. A gluten-
free diet was suggested. On the sixth month follow-up, he felt more
fatigued, he had no clinical beneﬁt from the diet and repeated
physical examination revealed continuing diarrhea and weight loss
and bilateral pretibial þþþ/þþþ edema. Laboratory examination
showed white blood cell: 12,500/mm3, hemoglobin: 13.2 g/dL,
platelet: 542,000/mm3, erithrocyte sedimentation rate: 115 mm/h,
serum albumin: 1.23 g/dL, urea: 61 mg/dL, creatinin: 1.34 mg/dL,
calcium: 7.53 mg/dL, AST: 39 IU/L, ALT: 25 IU/L, ALP: 479 IU/L, GGT:
68 IU/L, LDH: 682 IU/L, amylase: 74 IU/L, INR: 1.879, prothrombin
time: 26 s, INR: 1.879, urinary protein (spot): þþþ, 24-h urine
protein: 6880 mg/day, serum beta-2 microglobulin: 0.67 mg/dL,
serum p-ANCA: negative, c-ANCA: negative, anti-endomissial anti-
body IgA and Ig G: negative, anti-gliadin Ig A: negative, anti-gliadin
Ig G: negative, anti-nuclear antibody: negative, anti-dsDNA: nega-
tive. Serum protein electrophoresis revealed polyclonal gammop-
athy, gamma: 43.9% (9e16%), serum immunglobulin A: 7.04 g/L
(0.7e4 g/L), serum immunoglobulin G: 23.5 g/L (7e16 g/L), serum
immunoglobulin M: 1.09 g/L (0.4e2.3), serum immunoglobulin E:
33.83 IU/mL (0e85 IU/mL), serum immunoglobulin-light chain
kappa: 5.41 g/L (1.7e3-7), serum immunoglobulin-light chain
lambda: 3.49 g/L (0.9e2.1), urinary Bence Jones protein: negative.
Therewere no osteolytic lesions at the cranial and lumbosacral plain
radiographies. Bone marrow biopsy was normal and plasma cell
ratio was 5e10% and no monoclonality existed. As there were
multiple lymph nodes at the mediastinum, mediastinoscopic
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some eosinophilic material staining with congo red. Immunohis-
tochemically CD38 and CD138 were positive. Kappa and lambda
light chain restriction were not signiﬁcant. There was mass forma-
tion by abnormal extracellular proteinous material deposition and
plasma cell proliferation. The rectum biopsy resulted as colitis and
amyloidosis. The patient was diagnosed as primary amyloidosis
associated with multiple myeloma. A combined melpha-
lanedexamethasone treatment was considered and the patient was
asked to come formonthly follow-up.We could not perform clinical
follow-up because the patient did not apply for the control.
2. Discussion
There are three major subtypes of amyloidosis: primary,
secondary and hereditary amyloidosis.1 Primary amyloidosis, the
most common form, is a plasma disorder that affects mostly the
bone marrow, but is not associated with other diseases. The build-
up of amyloid protein primarily affects the heart, kidneys, lungs,
skin, tongue, nerves and intestines.1 It may also occur in association
with multiple myeloma. Secondary amyloidosis occurs in associa-
tion with chronic inﬂammatory or infectious diseases. Hereditary
or familial amyloidosis is rare and the only inherited form of the
disease.
In multiple myeloma-associated AL amyloidosis, precursor light
chains of immunoglobulin (Bence Jones protein, lambda light chain,
kappa light chain) are produced by malignant plasma cell clone in
large quantities and can be detected in serum or urine by electro-
phoresis. Multiple myeloma is a plasma cell malignancy. Amyloid-
osis develops in about 15% of patients of myelomatosis.2
Amyloid deposition in the gastrointestinal tractmay be localized
or diffuse, with the most common sites of gastrointestinal inv-
olvement being the descending duodenum (100%), stomach and
colorectum (>90%) and esophagus (70%).3 The deposits may in-
volve the mucosa, submucosa, muscularis mucosa, vasculature and
neuroganglionic structures.4
Endoscopically, the gastrointestinal mucosa in amyloidosis
often appears granular, fragile, polypoid, eroded and ulcerated.3
The second portion of the duodenum is affected most frequently
and severely because of malabsorbtion that presents and it is the
most absorbing part of the intestine. Diagnostic success rate of
gastrointestinal biopsies is highest from the tongue/gingiva and
liver (100%), followed by the rectum (94%), the small intestine and
stomach (86%) and ﬁnally, the colon (73%).5 Liver and tongue
biopsy are not recommended because of the possible increased
frequency of bleeding complications and the discomfort of the
patient, respectively.5
Clinically, involvement of the gastrointestinal tract with
amyloidosis may present as chronic intestinal dysmotility, malab-
sorption, protein-losing enteropathy and gastrointestinal bleeding.
As in our case, chronic diarrhea, malabsorption and protein-losingenteropathy are all existing. Firstly he was diagnosed as gluten
enteropathy but did not beneﬁt from gluten-restricted diet.
The usual presentation of renal amyloid is heavy proteinuria
and nephrotic syndrome. Renal failure is the leading cause of death
in systemic amyloidosis occurring in up to 50% of patients.6
More than 90% of patients with systemic amyloidosis have liver
involvement andmany have hepatomegaly.7 In our case the patient
had hepatomegaly and nephrotic range proteinuria. Oligoclonal
gammopathy usually presents in multiple myeloma; in our case
polyclonal gammopathy was existing but signiﬁcant increment of
Ig A, thoracic plasma cell inﬁltration, serum lambda and kappa light
chain, histopathological features, CD 38 and 138 positive immu-
nohistochemical ﬁndings led the diagnosis to multiple myeloma.
The polyclonality was a rare seen condition of the case.
3. Conclusion
This case illustrates the multisystem involvement of primary
amyloidosis and the possible rapidly deterioration. Although the
presentation was atypical, several features led us to primary
amyloidosis in association with multiple myeloma (The extensive
multisystemic involvement and the progressive deterioration rule
out the possibility of amyloidosis secondary to multiple myeloma.).
Chronic diarrhea, malabsorbtion, hepatomegaly and proteinuria
was a pointer to the diagnosis and makes sense to search for par-
aprotein, Bence Jones protein and serum immune electrophoresis.
If initiated, whether earlier chemotherapy would have lengthened
the patient’s life is uncertain.
Survival depends on how quickly the disease is diagnosed and
on how well the underlying condition is treated. Due to the co-
mplex nature of the disease process, the clinical manifestations of
amyloidosis are often overlooked or mistaken for another disease
process, thus delaying treatment of the disease course.1
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